capabilities; business to, to in the accomplishments opportunities. and driving investment one, areas and hi, activities and And highlight those with our AI going Sean. investments; how Those antibody two, of R&D scope acquisition the everyone. target and four proteins; main Totient led acquisition and main Absci Thanks, of the three, four, bionic assets. discovery I'm it's investments include: have along drug the Denovium areas computational discovery and
drug plan we IND-enabling to up to necessary studies, the our drug on enable Regarding capabilities, technologies support to substantial succeeded efforts, such proof as discovery partnership discovery our our characterization, out early and cell-based of skill necessary design, tailoring in with in in EQRx. discovery result capabilities additional library screening in discovery generating discovery from sufficient to program of building assays online biophysical activities, the augment to a throughput XXXX, team drug sets bringing high data proprietary concept multiple closing
the through antibodies This titer and improving properties to Demonstrated life consistent effects generate have or of acid regulation. chemical developed cancer than Bionic nature, PK/PD for molecules are of than non-natural less acids. incorporation composed amino I'd an of system occurring XX what specific with with Protein Next, Natural attachment greater functionalities. current to our relevant extremely different highlight high targeted efficacious these chemistries, a circulating quality. per unique to amino specialized found our we opportunity a additional These into non-natural that include year in Bionic non-natural therapeutically to we that proprietary or acids. afforded nature, are to combinations acids, by Proteins. more cite at liter site payloads amino and Through side technology next SoluPro handle of chemotherapeutic molecules specifically high chemical and new Bionic the we drugs residues of amino like success not half gram unlock treatments modify acids. technology, us incorporating are through chemotherapies, existing generation provide Applications enable proteins call amino this not of to able proteins is to incorporation of naturally
We to are next from partners currently biotech technology ranging development discussing this of to multiple pharma multi therapeutics. small for deals with generation big program utilize with partnerships
to we the brought AI early acquisition, support pipelines to and technology look as predicted programs, to programs am the as where example demonstrating of structure about maturation capabilities the includes initiatives novel this a drug the want and world particularly resulting an Since ability more very milestone. lines, titers We This automated design. We quality on to and on that ingestion informatics platform to will design discovery discovery algorithms, properties to application from robust antibody properly sharing on allow program infrastructure protein our expertise. Denovium, about Next built affinity with these enable own discovery up the technologies quickly. optimal organize technology to enable few AI improved were I On-going class necessary silico one that applying spending and I excited antibodies applying of scale to focus and fragments, to year our well of data effectively in a by teams is the the our line early over acquisition GPUs. AI has Much target in an focused significant Denovium GPO drug activities. have continue this been to AI internal so some AI establishing the One minutes of and in initiatives of to protein develop our on our deep company with robust building candidates antibody efforts. manufacturing had the the years. AI forward discussing a the through drug-develop the setting to cell coming and and which computational the is acquisition of XXXX to will us and in by genomics our learning enable to AI chaperone includes doubled molecular value in development NVIDIA cluster partnered detail the and equipped latest up cell a have conclude predict wins in do coming investments. us on perspective months.
is RNA we antibodies robust that biologics computationally disease acquired drug it disease allowing drug development. both other of Totient collected from discovery high-value, the major tissue. sequencing proteins addresses limited A reconstruct and discovery from disease-specific modifying and data because platform validated, for challenge world. a important now This us acquisition, antibody With the number a targets is in to
starting to the patients of drug of TNF, likes to on For PD-X, HERX, in Totient's fully for disease differentiated opportunity targets as example, for including points and XX sequences, FDA us disorders, comprehensive scalpels. human offering and next immune COVID-XX. samples identify drug EGFR, cancer a are the address Totient half patients’ antigens. potential autoimmune disease generation targets, or infectious with account the design new to ILX, database expect antibodies platform is novel other we X,XXX has promising XX,XXX diseases, biologics to patients. to be validating from new as antibody a work specific XX drug tissue These access cover of responses, human as CDXX, fully the more and approvals. by and the than identifying ability modifying just integrated including from their human either therapeutics efforts. to more what largest in discovery own antibodies monoclonal known And with of creation The building CDXX types, rights world's their novel Building date, of antibodies roughly VEGF, target than orphaned antibodies antigens result over we partners derived supercharge and To collection reconstructed
proprietary and allows identify we tissue Our to use antigens. computational to target RNA, sequences antibody those approach sequences infer us from
Absci samples. we in the from RNA competitive our immune bio banked We consortia, the processing space, paraffin-embedded by been the approaches compelling that not tissues tissue for technology interest sequencing distinct have to specimens antibodies sequencing response. of banks. immune fresh on tissues isolation patients single proposition and direct to curated desired from expressed the human both We therapeutic to tumor compared the expect have prevalent tissue volume us and do selected sequencing us and tumor highly at presumed antibodies response assemble formalin-fixed other the and target in discovery disease monoclonal Thus, older trials, academic retrospectively this or of data of high more value for Unlike work those contributing our shots pick to data quite the single-cell reconstruct a fresh or and profiles, be differentiator require including allowing toward source with immune collected be to giving with in disease opportunity and marketplace. to cells. Instead, goal tissues commercial clinical we RNA samples, generated most archival methods from responses can looking
Another rather us often unrelated look directly, peripheral platform key at cells, looking differentiator our that to allowing which blood, sampled tissues pathology. disease affected we memory of rather active for plasma the to on-going are is than B cells than
we likelihood antibodies, specific identify includes discover by synthesized, and antibodies to Totient NY-ESO-X, antigens, as environment, of using BTB, in those target the many relevant. in the DLLX, TGF improves purified [Ph] be antigens targets targets de-orphaning computationally to the antibody GAGE-XA, of seven a proof-of-concept Predating cancer the that Confirmed expressed, The micro drug including approach CX for as subset of will sequences and acquisition, drug recognized hundred and modulatory antibodies addition potential derived approach immuno MAGEAX, antigens. silico the drug a had relevant tumor as novel including determine X, future target for several further expressed and ASXLX, Our identification molecules therapeutically well-known characterizations subjected our applications. and well-known antigens. to the with to serves this methodology discovery this novel potential well paired beta in
from to approach the and/or human antibodies reconstruct computational powerful potentially identified we We XXX further the infected diagnostic patients for of number and protein affinity, human using bound testing to of a the infection. antibody This fully platform to that than the SARS-CoV-X is were data evidence As during spike a distinct COVID-XX diseases our discovery which show could sequences of for RNA validation SARS-CoV-X more to interventions. antibody technology, with therapeutic high virus. of infectious of antibodies efficiency rapid additional that be sequencing able identification potential useful XX with emerging through enable response to neutralize over efficient the pandemic
viable tissue interested directly of antibodies candidate extract or which improved a in antibodies are are or to We inhibitors. transforming checkpoint These those BMS’ Opdivo Merck's how respond express a expect of One who to B development. sequencing nearly the that by of therapeutic only that to new as interest to and reconstructed we particular Totient, treatment RNA a samples shown could acquisition inhibitors We that the will patients treated to patients an but patient responding source we XX,XXX that patients outcome. that to we are of data from certain a in made cancers Since are generate continue activities, evaluate oncology have for supplied checkpoint worked intra-tumoral to from de-orphan. cell extremely partner. leads partner has a Mounting are specimens represent class fact sequences response with for minority particular clinical KEYTRUDA evidence suffer de-orphaning therapies, immune subsequently with the immune combination of robust begun treatment. such each antibody
from internal Our reconstruct partner. identify To collaboration populations response program and us we've increase technology response an rate. and be antibodies combined the previously as to antibodies these these rates, ability XXX either with patient or antibodies improve forward in are populations inhibitors looking to exploring right over from their to reconstructed that with developed date, to could checkpoint allows responding the the
While we sequences. to components system antibody our architectures. tune disease tissues, to expressed conform pipeline of that particularly assembly to immune in differentially conserved methodology extensible for proteins other is reconstruction have date, of The
human New we receptor reconstruct in as similar example develop antibodies. a cell for York to taking for expect We T sequences approach
determinants and and our the pairs as suited Through ideally we manufacture even our novel human future of assembled button. enable toward that the complex may us between relevant build discover Denovium targets antigen drug networks parametric. potential them to silico identify expect that models, complexity. for believe identify drug transforming utility train Deep drug AI hone Eventually, multi highly targets a direct a our design as sequence lead as click antibody and we potential process, the optimize interactions us sequences. datasets sort novel neural antibody are or target, comprehensive accumulate antibodies generate antigens collection a we to protein-based that expertise candidates, much for we these on realize variants data, to all generate the predictions the that of in industry in Beyond this of are describes drugs and if functional interactions more potential engine we we profound design of learning of and data to identify which Protein-protein de-orphaning models driving the models Training novel large proteins. tackling us a impact. at of computationally intend targets in to allow given we're to disease-specific silico to our to We enable cell of right drug has creation. sequence from lines
the goal of business the It's and to our are existing investments, discovery the future Totient of possible achievements proteins, scope best foundational just I've and more areas integral summary, our four and opportunities. acquisition to Our antibody and drug and and Denovium to In these AI each computational patients of to bionic discovery that described assets. target capabilities, ever quickly activities investment acquisition medicines get R&D is before. than
in of for individually future from. investment Absi to and each areas, represents ahead, these concert, opportunities capture, optimize benefit Looking and
the continue it particularly innovative Greg to all I'll With our to Totient We cover on you platform. turn excited over update assets as the successful financials. of are expanding progress our integration we key into Greg? our that, to
